RCAMU
FOLD

Rothschild & Co Asset Management US’s Amicus Therapeutics FOLD Stock Holding History

Rothschild & Co Asset Management US’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$8.13M Sell
666,214
-47,732
-7% -$537K 0.12% 125
2022
Q3 		$7.45M Sell
713,946
-158,654
-18% -$1.77M 0.13% 134
2022
Q2 		$9.37M Sell
872,600
-42,015
-5% -$346K 0.14% 125
2022
Q1 		$8.66M Sell
914,615
-299,502
-25% -$2.81M 0.11% 153
2021
Q4 		$14M Sell
1,214,117
-47,046
-4% -$524K 0.16% 140
2021
Q3 		$12M Sell
1,261,163
-146,768
-10% -$1.5M 0.15% 165
2021
Q2 		$13.6M Buy
1,407,931
+262,337
+23% +$2.56M 0.16% 162
2021
Q1 		$11.3M Sell
1,145,594
-336,873
-23% -$5.21M 0.14% 183
2020
Q4 		$34.2M Sell
1,482,467
-281,263
-16% -$5.75M 0.44% 64
2020
Q3 		$24.9M Buy
1,763,730
+19,273
+1% +$281K 0.45% 83
2020
Q2 		$26.3M Sell
1,744,457
-288,663
-14% -$3.52M 0.39% 97
2020
Q1 		$18.8M Sell
2,033,120
-167,787
-8% -$1.59M 0.29% 135
2019
Q4 		$21.4M Buy
2,200,907
+682,567
+45% +$6.25M 0.22% 185
2019
Q3 		$12.2M Sell
1,518,340
-16,083
-1% -$175K 0.13% 242
2019
Q2 		$19.1M Buy
1,534,423
+43,483
+3% +$552K 0.2% 190
2019
Q1 		$20.3M Sell
1,490,940
-30,399
-2% -$371K 0.22% 179
2018
Q4 		$14.6M Buy
1,521,339
+21,653
+1% +$238K 0.18% 206
2018
Q3 		$18.1M Buy
1,499,686
+1,264,173
+537% +$17.7M 0.19% 205
2018
Q2 		$3.68M Buy
235,513
+139,382
+145% +$2.11M 0.04% 311
2018
Q1 		$1.45M Buy
96,131
+3,622
+4% +$55.1K 0.02% 332
2017
Q4 		$1.33M Buy
+92,509
New +$1.27M 0.01% 332

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Rothschild & Co Asset Management US's FOLD Position: Q4 2022 in Review

Rothschild & Co Asset Management US reduced its Amicus Therapeutics (FOLD) stake by 6.7% in Q4 2022, selling an estimated $537K and leaving 666,214 shares worth $8.13M. The position accounts for 0.12% of the portfolio, ranked #125.

Rothschild & Co Asset Management US first reported a position in FOLD in Q4 2017 and has held it in 21 quarters since. The position peaked at $34.2M in Q4 2020. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

  • Rothschild & Co Asset Management US held 666,214 shares of Amicus Therapeutics worth $8.13M as of Q4 2022.
  • Rothschild & Co Asset Management US sold 47,732 Amicus Therapeutics shares in Q4 2022, an estimated $537K.
  • Amicus Therapeutics made up 0.12% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #125 holding.
  • Rothschild & Co Asset Management US first reported a position in Amicus Therapeutics in Q4 2017 and has held it in 21 quarters since.
  • Rothschild & Co Asset Management US's Amicus Therapeutics position peaked at $34.2M in Q4 2020.
  • 230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.